Eton Pharmaceuticals, Inc. Contracts & Agreements

Offer Letter Agreement by and between the Registrant and James Gruber, dated as of March 25, 2022 (Filed With SEC on March 16, 2023)

Asset Purchase Agreement by and among the Company and Dr. Reddys Laboratories S.A., dated as of June 24, 2022 (Filed With SEC on August 11, 2022)

Credit Agreement by and among the Company, the Lenders party thereto, and SWK Funding LLC , as administrative agent dated as of November 13, 2019 and conformed through Third... (Filed With SEC on May 12, 2022)

Underwriting Agreement, dated as of April 8, 2021, by and among Eton Pharmaceuticals, Inc., Harrow Health, Inc. and National Securities Corporation (Filed With SEC on April 8, 2021)

Description of Securities of the Registrant (Filed With SEC on March 16, 2021)

2018 Equity Incentive Plan (as amended December 2020 (Filed With SEC on March 16, 2021)

Underwriting Agreement between the Company and National Securities Corporation dated October 14, 2020 (Filed With SEC on October 14, 2020)

Promissory Note between Eton Pharmaceuticals, Inc. and Bank of America, NA (Filed With SEC on May 6, 2020)

Securities Purchase Agreement dated March 26, 2020 by and between the Company and Opaleye L.P (Filed With SEC on March 30, 2020)

Purchase Agreement dated March 26, 2020 by and among the Company and Certain Investors (Filed With SEC on March 30, 2020)

First Amendment to Credit Agreement dated as of March 26, 2020 by and between the Company and SWK Funding LLC, as Agent (Filed With SEC on March 30, 2020)

Warrant dated November 13, 2019 issued to SWK Holdings LLC (Filed With SEC on March 5, 2020)

Credit Agreement dated as of November 13, 2019, by and among the Company and SWK Funding LLC (Filed With SEC on March 5, 2020)

Exclusive License and Product Development Agreement between Eton Pharmaceuticals, Inc. and Aucta Pharmaceuticals, Inc., effective as of July 30, 2019 (but executed as of June 12,... (Filed With SEC on November 14, 2019)

Agreement between Eton Pharmaceuticals, Inc. and Bausch Health Ireland Limited (BIRL), dated as of February 18, 2019 (Filed With SEC on May 7, 2019)

Agreement between Eton Pharmaceuticals, Inc. and Sintetica SA, dated as of February 8, 2019 (Filed With SEC on May 7, 2019)

Agreement between Eton Pharmaceuticals, Inc. and Liqmeds Worldwide Limited, dated as of January 23, 2019 (Filed With SEC on May 7, 2019)

Agreement between Eton Pharmaceuticals, Inc. and Sintetica SA, dated as of February 8, 2019 (Filed With SEC on May 7, 2019)

Agreement between Eton Pharmaceuticals, Inc. and Harrow Health Inc., dated as of May 6, 2019 (Filed With SEC on May 7, 2019)

Agreement between Eton Pharmaceuticals, Inc. and Eyemax LLC, dated as of February 18, 2019 (Filed With SEC on May 7, 2019)

Form of Underwriting Agreement (Filed With SEC on November 5, 2018)

Specimen Certificate representing shares of common stock of Registrant (Filed With SEC on November 5, 2018)

Form of Underwriters Warrant (Filed With SEC on November 5, 2018)

Form of Underwriting Agreement (Filed With SEC on October 31, 2018)

Specimen Certificate representing shares of common stock of Registrant (Filed With SEC on October 31, 2018)

Form of Underwriters Warrant (Filed With SEC on October 31, 2018)

Exclusive Sales and Marketing Agreement (EM-100) dated August 11, 2017 between Eyemax, LLC and the Registrant (Filed With SEC on October 18, 2018)

Development, Supply and Commercialization Agreement (CT-100) dated November 7, 2017 between Amphastar Pharmaceuticals, Inc. and the Registrant (Filed With SEC on October 18, 2018)

Exclusive License and Supply Agreement (ET-103) dated August 3, 2018 between the Registrant, Liqmeds Worldwide Limited and LM Manufacturing, Ltd (Filed With SEC on October 18, 2018)

2017 Equity Incentive Plan (Filed With SEC on October 18, 2018)

2018 Equity Incentive Plan (Filed With SEC on October 18, 2018)

2018 Employee Stock Purchase Plan (Filed With SEC on October 18, 2018)

Exclusive Sales and Marketing Agreement (EM-100) dated August 11, 2017 between Eyemax, LLC and the Registrant (Filed With SEC on September 25, 2018)

Development, Supply and Commercialization Agreement (CT-100) dated November 7, 2017 (Filed With SEC on September 25, 2018)

Exclusive License and Supply Agreement (ET-103) dated August 3, 2018 between the Registrant, Liqmeds Worldwide Limited and LM Manufacturing, Ltd (Filed With SEC on September 25, 2018)

2017 Equity Incentive Plan (Filed With SEC on September 25, 2018)

2018 Equity Incentive Plan (Filed With SEC on September 25, 2018)

2018 Employee Stock Purchase Plan (Filed With SEC on September 25, 2018)

Amendment No. 1 dated August 29, 2018 to Sales/Marketing Agreement (DS-300) dated November 17, 2017 between AL Pharma, Inc. and the Registrant (Filed With SEC on September 25, 2018)

Warrant dated May 4, 2017 issued to Liquid Patent Advisors, LLC (Filed With SEC on August 10, 2018)

Warrant dated June 26, 2017 issued to National Securities Corporation (Filed With SEC on August 10, 2018)

Securities Purchase Agreement dated June 19, 2017 by and among the Registrant and the Buyers named therein (Filed With SEC on August 10, 2018)

Registration Rights Agreement dated June 19, 2017 by and among the Registrant and certain of its stockholders (Filed With SEC on August 10, 2018)

Asset Purchase and License Agreement (CT-100) dated May 9, 2017 between Imprimis Pharmaceuticals, Inc. and the Registrant (Filed With SEC on August 10, 2018)

Asset Purchase and License Agreement (CT-200) dated May 9, 2017 between Imprimis Pharmaceuticals, Inc. and the Registrant (Filed With SEC on August 10, 2018)

Asset Purchase Agreement (DS-200) dated June 23, 2017 between Selenix, LLC and the Registrant (Filed With SEC on August 10, 2018)

Exclusive Development and Supply Agreement (DS-100) dated July 9, 2017 between Andersen Pharma, LLC and the Registrant (Filed With SEC on August 10, 2018)

Exclusive Sales and Marketing Agreement (EM-100) dated August 11, 2017 between Eyemax, LLC and the Registrant (Filed With SEC on August 10, 2018)

Development, Supply and Commercialization Agreement (CT-100) dated November 7, 2017 (Filed With SEC on August 10, 2018)

Sales/Marketing Agreement (DS-300) dated November 17, 2017 by and among AL Pharma, Inc., SCS National, LLC, Dry Creek Project, LLC and the Registrant (Filed With SEC on August 10, 2018)

Eton Pharmaceuticals, Inc. 2017 Stock Incentive Plan (Filed With SEC on August 10, 2018)

Consulting Agreement by and between the Registrant and Mark L. Baum, dated as of May 1, 2017 (Filed With SEC on August 10, 2018)

Offer Letter Agreement by and between the Registrant and Sean E. Brynjelsen, dated as of May 17, 2017 (Filed With SEC on August 10, 2018)

Offer Letter Agreement by and between the Registrant and W. Wilson Troutman, dated as of June 27, 2017 (Filed With SEC on August 10, 2018)

Exclusive License and Supply Agreement (ET-103) dated August 3, 2018 between the Registrant, Liqmeds Worldwide Limited and LM Manufacturing, Ltd (Filed With SEC on August 10, 2018)